5 April 2018
Chief Investigator: Professor David Werring (UCL)
OPTIMAS is a multicentre randomised controlled trial of early vs standard, guideline-based timing of anticoagulation with a DOAC in patients with atrial fibrillation and acute ischaemic stroke.
Eligibility: Adult patients with nvAF and clinical diagnosis of acute ischaemic stroke, eligible for DOAC treatment.
Intervention: Anticoagulation with any DOAC within 4 days of acute ischaemic stroke
Control: Anticoagulation with any DOAC at 7—14 days of acute ischaemic stroke
Key Outcomes: combined incidence of symptomatic ICH, ischaemic stroke and systemic embolism at 90 days; intracranial and major extracranial bleeding
Imaging: encouraged but no specific requirements for study entry
Anticipated First Recruitment: February 2019
Target Sites: >100 in UK (70 EoI to date)
Interested? Email email@example.com